Monitoring Ravulizumab effect on complement assays

Willrich, MAV; Ladwig, PM; Martinez, MA; Sridharan, MR; Go, RS; Murray, DL

Willrich, MAV (corresponding author), Dept Lab Med & Pathol, Div Clin Biochem & Immunol, Rochester, MN 55905 USA.

JOURNAL OF IMMUNOLOGICAL METHODS, 2021; 490 ():

Abstract

Ravulizumab is a new C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索